Search

Alpana G Waldron

from Fairfield, CT
Age ~56
Get Report
Also known as:
Alpana Gupta, Alpana Gupta-Waldron, Alpana N
Related to:
Skyler C Gupta, 23
Connected to:
Amir H Waldron, 30Anna K Waldron, 87Cara D Waldroop, 46Christina Waldron, 51Christy S Waldron, 52Cliff A Waldron, 69Dallas Waldron, 30Darlene G Waldron, 59Darryl Waldron, 48Eric S Waldron, 49

Alpana Waldron Phones & Addresses

  • Fairfield, CT
  • Trumbull, CT
  • Stamford, CT
  • Basking Ridge, NJ
  • Mount Sinai, NY
  • Union, NJ
  • Houston, TX
  • Morristown, NJ
  • 209 Mailands Rd, Fairfield, CT 06824 (203) 254-1891

Education

Degree: Graduate or professional degree

Emails

d***[email protected]

Resumes

Resumes

Alpana Waldron Photo 1

President

View page
Location:
Fairfield, CT
Industry:
Pharmaceuticals
Work:
Omega-4 Data Solutions
President
Cara Therapeutics
Associate Director Biostatistics
Bristol-Myers Squibb May 2016 - Nov 2018
Associate Director Biostatistics
Inventiv Health Clinical 2014 - 2016
Principal Biostatistician
Purdue Pharma L.p. 2007 - 2014
Assistant Director, Biostatistics
Education:
Stony Brook University
Bachelors, Bachelor of Science, Applied Mathematics Stony Brook University
Master of Science, Masters, Statistics
Skills:
Pharmaceutical Industry
Cro
Clinical Trials
Clinical Research
Fda
Sas Programming
Project Management
Biostatistics
Cdisc
Biotechnology
Standards Development
Sas
Oncology
Cro Management
Data Management
Vendor Management
Medidata
Sharepoint
Nda
Nquery
Electronic Common Technical Document Specification
Gcps
Alpana Waldron Photo 2

Alpana Waldron

View page

Publications

Us Patents

Src Activation For Determining Cancer Prognosis And As A Target For Cancer Therapy

View page
US Patent:
20100081666, Apr 1, 2010
Filed:
Jul 14, 2009
Appl. No.:
12/503019
Inventors:
Christina M. COUGHLIN - Berwyn PA, US
Michael E. BURCZYNSKI - Cedar Knolls NJ, US
Marisa P. DOLLED-FILHART - New Haven CT, US
Robert PINARD - Andover MA, US
Donald WALDROM - Fairfield CT, US
Charles ZACHARCHUK - Westford MA, US
Frederick IMMERMANN - Suffern NY, US
Maha KARNOUB - Doylestown PA, US
Jason CHRISTIANSEN - Glastonbury CT, US
Mark GUSTAVSON - Niantic CT, US
Annette MOLINARO - New Haven CT, US
Alpana Waldron - Fairfield CT, US
Assignee:
Wyeth - Madison NJ
International Classification:
A61K 31/506
C12Q 1/68
C12Q 1/48
C12Q 1/02
US Classification:
51425219, 435 6, 435 15, 435 29, 51425306, 514275
Abstract:
Methods of cancer diagnosis and prognosis using biomarkers.

Correlation Of Molecular Markers With Clinical Outcome In Gbm Patients Radiation Treated With Or Without Gefitinib

View page
US Patent:
20100144540, Jun 10, 2010
Filed:
Sep 22, 2009
Appl. No.:
12/564698
Inventors:
Arnab Chakravarti - Dublin OH, US
Robert Pinard - Andover MA, US
Donald Waldron - Fairfield CT, US
Agnes Ang - Newbury Park CA, US
Marisa P. Dolled-Filhart - New Haven CT, US
Annette Molinaro - New Haven CT, US
Alpana Waldron - Fairfield CT, US
International Classification:
C40B 30/00
G01N 33/53
US Classification:
506 7, 435 71
Abstract:
Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.

Association Of Biomarkers With Patient Outcome

View page
US Patent:
20120270233, Oct 25, 2012
Filed:
Feb 10, 2009
Appl. No.:
12/866836
Inventors:
Donald E. Waldron - Fairfield CT, US
Alpana Waldron - Fairfield CT, US
Robert Pinard - Andover MA, US
Mark Gustavson - Niantic CT, US
International Classification:
G01N 21/64
C12Q 1/02
C12Q 1/48
G01N 21/17
US Classification:
435 74, 435 29, 435 15
Abstract:
The present method relates to quantification of prognostic and predictive biomarkers of the PDK/AKT/mTOR pathway, such as GSK3β, S6, CREB, PTEN, AKT and mTOR, using AQUA analysis to estimate both patient risk and benefit of treatment to patients diagnosed with glioblastoma. Unlike traditional IHC, the AQUA system is objective and produces quantitative in situ protein expression data on a continuous scale. Taking advantage of the power of the AQUA system, the present method provides a highly robust and standardized diagnostic assays that can be used in the clinical setting to provide physicians with reliable prognostic and predictive information. Glioblastoma multiform (GBM) remains one of the most aggressive human cancers, and biomarkers that provide prognostic and predictive information would be extremely valuable to both the physician and the patient. A patient's risk may be determined using the prognostic biomarkers of the present method. Such a prognostic determination will allow physicians to identify patients with a relatively ‘good’ or a relatively ‘poor’ prognosis. The benefit of treating specific patients with a specific therapy, may be determined usin the predictive markers of the present method. Treatment with the AGC-family kinase inhibitor enzastaurin, for example, identifies patients that will likely benefit from treatment or not.
Control profile
Alpana G Waldron from Fairfield, CT, age ~56 Get Report